Amarin Corporation plc (AMRN) Income Statement Analysis

See more : HDFC Asset Management Company Limited (HDFCAMC.NS) Income Statement Analysis – Financial Results

Complete financial analysis of Amarin Corporation plc (AMRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amarin Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Amarin Corporation plc (AMRN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.amarincorp.com

About Amarin Corporation plc

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993
Revenue	306.91M	369.19M	583.19M	614.06M	429.76M	229.21M	181.10M	130.08M	81.76M	54.20M	26.35M	0.00	0.00	0.00	0.00	0.00	7.37M	500.00K	500.00K	1.02M	7.37M	65.51M	53.77M	17.55M	11.22M	19.00M	24.30M	21.50M	29.10M	18.70M	14.70M
Cost of Revenue	141.37M	126.71M	121.33M	131.44M	96.02M	54.54M	44.95M	34.36M	27.88M	20.49M	11.91M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	107.00K	11.91M	30.13M	21.46M	5.22M	2.98M	3.70M	2.80M	4.00M	4.90M	0.00	3.10M
Gross Profit	165.54M	242.48M	461.86M	482.62M	333.74M	174.67M	136.15M	95.72M	53.88M	33.72M	14.44M	0.00	0.00	0.00	0.00	0.00	7.37M	500.00K	500.00K	910.00K	-4.55M	35.38M	32.32M	12.33M	8.24M	15.30M	21.50M	17.50M	24.20M	18.70M	11.60M
Gross Profit Ratio	53.94%	65.68%	79.20%	78.59%	77.66%	76.20%	75.18%	73.58%	65.90%	62.21%	54.79%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	89.48%	-61.74%	54.01%	60.10%	70.25%	73.47%	80.53%	88.48%	81.40%	83.16%	100.00%	78.91%
Research & Development	22.22M	30.41M	29.31M	38.96M	34.39M	55.90M	47.16M	49.98M	51.06M	50.33M	72.75M	58.96M	21.60M	28.01M	17.84M	12.95M	12.11M	17.19M	8.31M	3.48M	5.44M	6.22M	4.14M	5.75M	7.44M	19.80M	19.80M	0.00	0.00	0.00	0.00
General & Administrative	88.61M	118.80M	141.86M	112.66M	323.62M	180.18M	112.04M	93.40M	93.07M	79.35M	121.25M	57.79M	22.56M	17.09M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	111.33M	185.61M	266.47M	350.65M	0.00	46.82M	22.51M	17.97M	7.97M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	199.94M	304.42M	408.33M	463.31M	323.62M	227.00M	134.55M	111.37M	101.04M	79.35M	121.25M	57.79M	22.56M	17.09M	15.25M	15.23M	19.46M	13.27M	9.77M	9.03M	30.89M	23.66M	33.26M	9.14M	5.30M	9.70M	7.30M	34.60M	18.60M	0.00	9.90M
Other Expenses	10.97M	-740.00K	-302.00K	104.00K	-75.00K	-326.00K	74.00K	-482.00K	-228.00K	3.73M	-1.19M	-427.00K	0.00	0.00	-2.16M	0.00	9.17M	674.00K	676.00K	-510.00K	-2.05M	39.24M	0.00	-1.00K	2.32M	2.60M	2.50M	1.20M	1.00M	0.00	600.00K
Operating Expenses	233.13M	334.83M	437.64M	502.27M	358.02M	282.90M	181.71M	161.35M	152.10M	129.67M	194.00M	116.75M	44.16M	45.10M	30.93M	28.18M	40.73M	31.13M	18.76M	12.00M	34.27M	69.12M	37.40M	14.89M	15.05M	32.10M	29.60M	35.80M	19.60M	0.00	10.50M
Cost & Expenses	374.50M	461.54M	558.97M	633.72M	454.03M	337.44M	226.66M	195.71M	179.98M	150.16M	205.91M	116.75M	44.16M	45.10M	30.93M	28.18M	40.73M	31.13M	18.76M	12.11M	46.19M	99.25M	58.85M	20.11M	18.03M	35.80M	32.40M	39.80M	24.50M	0.00	13.60M
Interest Income	11.86M	2.82M	1.22M	4.90M	8.50M	1.07M	429.00K	234.00K	132.00K	96.00K	343.00K	544.00K	231.00K	53.00K	780.00K	9.63M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	8.00K	15.00K	129.00K	2.61M	6.63M	7.80M	9.77M	18.44M	20.05M	18.48M	34.18M	18.09M	1.00K	19.00K	8.23M	2.14M	6.46M	0.00	1.80M	0.00	0.00	29.46M	0.00	0.00	0.00	24.40M	800.00K	0.00	0.00	0.00	0.00
Depreciation & Amortization	2.97M	3.09M	2.86M	2.05M	862.56K	667.87K	715.59K	777.59K	812.00K	844.00K	892.00K	449.00K	76.00K	63.00K	582.00K	251.00K	386.00K	795.00K	810.00K	754.00K	671.00K	8.29M	21.22M	2.42M	2.32M	2.60M	2.50M	1.20M	1.00M	0.00	600.00K
EBITDA	-50.90M	-100.65M	14.28M	-12.71M	-15.06M	-106.63M	-44.82M	-56.53M	-97.41M	-39.78M	-134.62M	-152.32M	-66.79M	-249.90M	-55.16M	-19.87M	-38.44M	-31.16M	-19.29M	-9.85M	-6.09M	-25.45M	16.14M	-224.00K	-4.81M	-7.90M	-5.60M	-17.10M	5.60M	18.70M	1.70M
EBITDA Ratio	-16.59%	-24.45%	4.31%	-2.39%	-3.69%	-47.36%	-24.49%	-50.82%	-120.42%	-170.16%	-681.23%	0.00%	0.00%	0.00%	0.00%	0.00%	-437.07%	-6,280.80%	-3,358.80%	-3,309.93%	-732.53%	6.42%	29.96%	-2.85%	-27.11%	-8.95%	-15.64%	-87.44%	16.15%	100.00%	9.52%
Operating Income	-67.59M	-92.34M	22.28M	-19.66M	-24.28M	-108.23M	-45.56M	-65.63M	-98.22M	-95.96M	-182.11M	-116.75M	-44.16M	-45.10M	-52.30M	-28.18M	-40.73M	-31.16M	-18.91M	-11.09M	-38.82M	-32.66M	-5.08M	-2.56M	-6.81M	-16.80M	-8.10M	-18.30M	4.60M	18.70M	1.10M
Operating Income Ratio	-22.02%	-25.01%	3.82%	-3.20%	-5.65%	-47.22%	-25.15%	-50.45%	-120.14%	-177.03%	-691.08%	0.00%	0.00%	0.00%	0.00%	0.00%	-553.06%	-6,232.20%	-3,781.60%	-1,090.66%	-527.10%	-49.86%	-9.44%	-14.59%	-60.71%	-88.42%	-33.33%	-85.12%	15.81%	100.00%	7.48%
Total Other Income/Expenses	13.92M	2.06M	789.00K	2.40M	1.80M	-8.12M	-9.26M	-10.76M	-20.07M	36.75M	12.69M	-54.20M	-22.73M	-204.92M	-29.36M	7.22M	-7.08M	3.64M	-2.35M	222.00K	12.24M	-883.00K	-298.00K	525.00K	-1.63M	-5.50M	-3.20M	1.60M	900.00K	0.00	200.00K
Income Before Tax	-53.67M	-103.81M	11.29M	-17.26M	-22.48M	-116.35M	-54.82M	-76.38M	-118.29M	-59.20M	-169.42M	-170.07M	-66.61M	-250.09M	-59.76M	-20.70M	-39.03M	-27.72M	-19.41M	11.35M	-26.58M	-33.55M	-4.71M	-2.22M	-10.15M	-30.10M	-11.30M	-16.70M	5.50M	0.00	1.30M
Income Before Tax Ratio	-17.49%	-28.12%	1.94%	-2.81%	-5.23%	-50.76%	-30.27%	-58.72%	-144.69%	-109.22%	-642.94%	0.00%	0.00%	0.00%	0.00%	0.00%	-529.99%	-5,543.80%	-3,881.00%	1,115.54%	-360.90%	-51.21%	-8.76%	-12.66%	-90.48%	-158.42%	-46.50%	-77.67%	18.90%	0.00%	8.84%
Income Tax Expense	5.44M	2.00M	3.56M	745.00K	164.00K	96.00K	13.05M	9.97M	-3.09M	-2.84M	-3.19M	9.12M	2.52M	-501.00K	-440.00K	-674.00K	-837.00K	-799.00K	-698.00K	7.33M	-7.36M	3.54M	412.00K	342.00K	-27.00K	100.00K	600.00K	-1.10M	1.40M	15.90M	500.00K
Net Income	-59.11M	-105.80M	7.73M	-18.00M	-22.65M	-116.45M	-67.87M	-86.35M	-115.20M	-56.36M	-166.23M	-179.18M	-69.13M	-249.59M	-59.32M	-20.02M	-38.20M	-26.92M	-18.71M	4.01M	-19.22M	-37.08M	-4.76M	2.36M	4.37M	-28.80M	-7.70M	-15.60M	4.10M	2.80M	900.00K
Net Income Ratio	-19.26%	-28.66%	1.33%	-2.93%	-5.27%	-50.80%	-37.47%	-66.38%	-140.91%	-103.99%	-630.82%	0.00%	0.00%	0.00%	0.00%	0.00%	-518.63%	-5,384.00%	-3,741.40%	394.49%	-261.02%	-56.61%	-8.85%	13.43%	38.96%	-151.58%	-31.69%	-72.56%	14.09%	14.97%	6.12%
EPS	-0.15	-0.26	0.02	-0.05	-0.07	-0.39	-0.25	-0.41	-0.64	-0.32	-1.03	-1.24	-0.53	-2.49	-1.40	-0.91	-4.08	-3.35	-4.63	1.72	-11.24	-39.71	-0.67	6.42	2.90	-19.29	-52.00	-110.00	31.00	20.00	8.00
EPS Diluted	-0.15	-0.26	0.02	-0.05	-0.07	-0.39	-0.25	-0.41	-0.64	-0.32	-0.99	-1.24	-0.53	-2.49	-1.40	-0.91	-4.08	-3.35	-4.63	1.72	-11.24	-39.71	-0.40	3.02	2.90	-19.29	-52.00	-110.00	31.00	20.00	8.00
Weighted Avg Shares Out	407.66M	401.16M	395.99M	381.76M	342.54M	297.24M	270.65M	210.61M	179.59M	173.72M	161.02M	144.02M	130.25M	100.24M	42.42M	22.06M	9.37M	8.03M	4.04M	1.79M	1.71M	933.77K	7.12M	149.89K	1.50M	1.49M	148.08K	141.82K	132.26K	140.00K	112.50K
Weighted Avg Shares Out (Dil)	407.66M	401.16M	402.48M	381.76M	342.54M	297.24M	270.65M	211.87M	180.65M	173.82M	167.07M	144.02M	130.25M	100.24M	42.42M	22.06M	9.37M	8.03M	4.04M	1.79M	1.71M	933.77K	12.04M	842.09K	1.50M	1.49M	148.08K	141.82K	132.26K	140.00K	112.50K

Amarin Announces Results of Annual General Meeting of Shareholders

April 22, 2024globenewswire.com

- Shareholders Approve Share Repurchase Program of up to $50 Million - - Shareholders Approve Share Repurchase Program of up to $50 Million -

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

April 15, 2024globenewswire.com

DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its...

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

April 8, 2024globenewswire.com

Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

April 6, 2024globenewswire.com

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) –

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

April 4, 2024zacks.com

Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.

Why Amarin Stock Was Rocketing Higher on Wednesday

April 3, 2024fool.com

Amarin's Vazkepa notched a crucial win with a European regulator. The medication earned an extension to its patent exclusivity on that market.

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

April 3, 2024globenewswire.com

Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039 Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

March 25, 2024globenewswire.com

-- Subgroup Analyses from REDUCE-IT ® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient...